Suppr超能文献

良性血液系统疾病中的移植后噬血细胞性淋巴组织细胞增生症:4例经验及文献复习

Post-transplant Hemophagocytic Lymphohistiocytosis in Benign Hematological Disorders: Experience of 4 Cases with Review of Literature.

作者信息

Garg Akanksha, Shah Sandip, Patel Kinnari, Shah Kamlesh, Anand Asha, Panchal Harsha, Patel Apurva, Parikh Sonia

机构信息

Department of Medical Oncology, Gujarat Cancer and Research Institute, Ahmedabad, Gujarat 380016 India.

出版信息

Indian J Hematol Blood Transfus. 2020 Oct;36(4):674-679. doi: 10.1007/s12288-020-01258-z. Epub 2020 Feb 24.

Abstract

Post transplant Hemophagocytic lymphohistiocytosis (HLH) is a form of secondary HLH, which can be either early onset or late onset and is associated with significant morbidity and mortality. With the increasing popularity of post transplant cyclophosphamide based haploidentical stem cell transplantation (SCT), post transplant HLH is becoming a significant complication especially in benign hematological disorders. Methods: We present 4 cases of post transplant HLH occurring in 2 cases of severe aplastic anemia (post haploidentical SCT) and 2 cases of thalassemia major (post matched sibling SCT). All 4 cases had early onset variety with dismal prognosis. Conclusion: Post-transplant HLH is an important entity in benign hematological disorders, which needs to be identified early and treated promptly with steroids, monoclonal agents or immunosuppressive therapy. Serum ferritin levels are an important biomarker and help in monitoring response.

摘要

移植后噬血细胞性淋巴组织细胞增生症(HLH)是继发性HLH的一种形式,可早发或晚发,且与显著的发病率和死亡率相关。随着基于移植后环磷酰胺的单倍体相合干细胞移植(SCT)越来越普及,移植后HLH正成为一种重要的并发症,尤其是在良性血液系统疾病中。方法:我们报告了4例移植后HLH病例,其中2例发生在重型再生障碍性贫血患者(单倍体相合SCT后),2例发生在重型地中海贫血患者(同胞全相合SCT后)。所有4例均为早发型,预后不佳。结论:移植后HLH在良性血液系统疾病中是一个重要问题,需要早期识别并及时用类固醇、单克隆药物或免疫抑制疗法进行治疗。血清铁蛋白水平是一个重要的生物标志物,有助于监测治疗反应。

相似文献

引用本文的文献

本文引用的文献

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验